Form 4: Director Shelley Chu Purchases Odyssey Therapeutics Shares

Director Shelley Chu acquired 11,111 shares of Odyssey Therapeutics, Inc. (ODTX) at $18 per share in the company's IPO.

Summary

• Director Shelley Chu purchased 11,111 shares of common stock in Odyssey Therapeutics, Inc.
• The transaction occurred on May 11, 2026, at a price of $18.00 per share.
• The acquisition was made as part of the company's initial public offering.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of insider confidence, though it is a routine disclosure of an IPO-related purchase.

Positives

• Insider confidence is demonstrated by a director purchasing shares at the IPO price.

Negatives

• None identified.

Risks

• Investment in initial public offerings carries inherent market volatility and liquidity risks.

Future Outlook

Not applicable as this is a transaction disclosure.

Industry Context

StockSavvy.ai notes that director participation in an IPO is generally viewed as a positive signal of alignment between leadership and public shareholders in the biotechnology sector.

Comparison to Industry Standards

• Director participation in IPOs is a standard practice for biotech firms to signal confidence to institutional and retail investors.

Stakeholder Impact

• Shareholders may view the director's investment as a sign of long-term commitment to the company's success.

Next Steps

• None specified.

Key Dates

Keywords

ODTX, Odyssey Therapeutics, Insider Trading, Form 4, IPO, Shelley Chu